相关实验视频

Updated: Jan 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

HKI-357通过通过AKT信号通路向UBE2C来抑制抵抗割的前列腺癌

Li Chen¹, Juan Zhang¹, Wenjun Liu²

¹Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China; Jiangsu Key Laboratory of Clinical Immunology, Soochow University, Suzhou 215006, China.

Biochemical pharmacology

|October 9, 2025

概括

一种新的化合物HKI-357通过向UBE2C蛋白质,有效地抑制了抗割的前列腺癌 (CRPC) 的生长. 这一发现为CRPC提供了一个有希望的治疗候选者,改善了患者的治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

前列腺癌 (PCa) 是一个常见的男性恶性瘤.
抗化前列腺癌 (CRPC) 发展出对雄激素剥夺疗法 (ADT) 的耐药性,导致预后不佳.
目前的CRPC疗法有效性有限,需要新的治疗方法.

研究的目的:

确定和评估CRPC的新型治疗剂.
为了研究HKI-357在CRPC中的作用机制.

主要方法:

对FDA批准的共价化合物库进行选.
在体外细胞活力和亡测定.
在小鼠体内异种移植研究.
异热定位热量计 (ITC),细胞热转移测定 (CETSA) 和分子对接来识别和验证药物标.
对基因和蛋白质表达水平和信号通路的分析.

主要成果:

在实验室中,HKI-357显著抑制了CRPC细胞活力,并诱导了亡.
在异种移植模型中,HKI-357抑制了瘤生长,没有明显的毒性.
UBE2C被确定为HKI-357的直接目标.
HKI-357治疗减少了UBE2C的表达,并抑制了AKT通路.
UBE2C在PCa和CRPC上调节,并且是雄激素受体 (AR) 的标.

结论:

HKI-357通过准UBE2C.表现出强大的抗CRPC活性.
该机制涉及下调UBE2C和抑制AKT通路的抑制.
HKI-357是CRPC治疗的一个有前途的治疗候选药物.

关键词:

在 AKT AKT 里面.这是一个HKI-3577.小分子抑制剂小分子抑制剂在 UBE2C 中,UBE2C 是

更多相关视频

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Murine Prostate Micro-dissection and Surgical Castration

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...